Login
$AZTA
$47.22 +$1.57 (3.44%) Live

$AZTA SEC Filings

Filed On Filing
16 Nov 2026 Form 4: Pirogova Olga, SVP and CHRO

Received 10,339 shares as a grant or award · Received 13,412 shares as a grant or award · Gave up 7,081 shares to cover exercise price or tax ($311K)

16 Nov 2026 Form 4: Lin Lawrence Y., EVP, CFO and Treasurer

Received 23,262 shares as a grant or award · Gave up 4,413 shares to cover exercise price or tax ($194K)

16 Nov 2026 Form 4
16 Nov 2026 Form 4
16 Nov 2026 Form 4
10 Nov 2026 8-K: Results of Operations and Financial Condition

Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026.

30 Oct 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more

Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities Exclusive licensing agreement with Elegen and acquisition of SynPlexity strengthen gene synthesis capabilities, expand high-thro...

23 Oct 2026 Form 4: Madaus Martin D, Interim CEO

Gave up 1,294 shares to cover exercise price or tax ($46.6K)

07 Oct 2026 8-K: Costs Associated with Exit or Disposal Activities; Material Impairments

On October 5, 2026, the Board of Directors of Azenta, Inc. (the “Company”) approved, and the Company committed to, a restructuring plan (the “Plan”) within the Company’s Multiomics reportable segment. The Plan is intended primarily to co...

23 Sep 2026 Form 4: Madaus Martin D, Interim CEO

Gave up 1,456 shares to cover exercise price or tax ($49.9K)

17 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

As previously disclosed in the Company’s Current Report on Form 8-K filed on August 24, 2026, the Board of Directors (the “Board”) of Azenta, Inc. (the “Company”) appointed Dr. Martin D. Madaus as the Company’s Interim President and Chie...

16 Sep 2026 Form 4: Madaus Martin D, Interim CEO

Received 36,653 shares as a grant or award

16 Sep 2026 Form 4: Martin William E. Iii, President Multiomics

Received 15,272 shares as a grant or award

16 Sep 2026 Form 4: Pirogova Olga, SVP and CHRO

Received 15,272 shares as a grant or award

16 Sep 2026 Form 4: Lin Lawrence Y., EVP, CFO and Treasurer

Received 30,544 shares as a grant or award

16 Sep 2026 Form 4: Starr Ephraim, SVP, Gen Counsel & Secretary

Received 15,272 shares as a grant or award

16 Sep 2026 Form 4: Bello Erik J., VP Chief Accounting Officer

Received 4,586 shares as a grant or award

09 Sep 2026 Form 3: Bello Erik J., VP Chief Accounting Officer

No securities owned

04 Sep 2026 8-K: Regulation FD Disclosure; Other Events

Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems BURLINGTON, Mass., September 4, 2026 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has received repayment in full, prior...

24 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

AZENTA ANNOUNCES LEADERSHIP TRANSITION Current Director Dr. Martin Madaus Appointed Interim CEO Company Reaffirms Previously Announced Fourth Quarter Fiscal 2026 Total Revenue Guidance BURLINGTON, Mass., August 24, 2026 – Azenta, Inc. (N...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support